Discovery of a first-in-class ANXA3 degrader for the treatment of triple-negative breast cancer

Triple-negative breast cancer (TNBC) is a nasty disease with extremely high malignancy and poor prognosis. Annexin A3 (ANXA3) is a potential prognosis biomarker, displaying an excellent correlation of ANXA3 overexpression with patients' poor prognosis. Silencing the expression of ANXA3 effectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Yongxi, Min, Delin, Fan, Hulin, Liu, Kunlin, Tu, Juchuanli, He, Xueyan, Liu, Bingjie, Zhou, Lu, Liu, Suling, Sun, Xun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149981/
https://www.ncbi.nlm.nih.gov/pubmed/37139408
http://dx.doi.org/10.1016/j.apsb.2022.11.023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149981/
https://www.ncbi.nlm.nih.gov/pubmed/37139408
http://dx.doi.org/10.1016/j.apsb.2022.11.023

Ejemplares similares